Seroatlas · Human Serome Atlas

LARS2

Leucine--tRNA ligase, mitochondrial

Also known as: KIAA0028, LEURS, MGC26121, mtLeuRS, SYLM_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q15031
Gene
LARS2
Ensembl
ENSG00000011376
Chromosome
3
Canonical length
903 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins
Subcellular location
Mitochondria

OverviewNCBI Gene

This gene encodes a class 1 aminoacyl-tRNA synthetase, mitochondrial leucyl-tRNA synthetase. Each of the twenty aminoacyl-tRNA synthetases catalyzes the aminoacylation of a specific tRNA or tRNA isoaccepting family with the cognate amino acid. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

903 residues, UniProt reviewed canonical sequence.

>Q15031|LARS2
     1  MASVWQRLGF YASLLKRQLN GGPDVIKWER RVIPGCTRSI YSATGKWTKE YTLQTRKDVE
    61  KWWHQRIKEQ ASKISEADKS KPKFYVLSMF PYPSGKLHMG HVRVYTISDT IARFQKMRGM
   121  QVINPMGWDA FGLPAENAAV ERNLHPQSWT QSNIKHMRKQ LDRLGLCFSW DREITTCLPD
   181  YYKWTQYLFI KLYEAGLAYQ KEALVNWDPV DQTVLANEQV DEHGCSWRSG AKVEQKYLRQ
   241  WFIKTTAYAK AMQDALADLP EWYGIKGMQA HWIGDCVGCH LDFTLKVHGQ ATGEKLTAYT
   301  ATPEAIYGTS HVAISPSHRL LHGHSSLKEA LRMALVPGKD CLTPVMAVNM LTQQEVPVVI
   361  LAKADLEGSL DSKIGIPSTS SEDTILAQTL GLAYSEVIET LPDGTERLSS SAEFTGMTRQ
   421  DAFLALTQKA RGKRVGGDVT SDKLKDWLIS RQRYWGTPIP IVHCPVCGPT PVPLEDLPVT
   481  LPNIASFTGK GGPPLAMASE WVNCSCPRCK GAAKRETDTM DTFVDSAWYY FRYTDPHNPH
   541  SPFNTAVADY WMPVDLYIGG KEHAVMHLFY ARFFSHFCHD QKMVKHREPF HKLLAQGLIK
   601  GQTFRLPSGQ YLQREEVDLT GSVPVHAKTK EKLEVTWEKM SKSKHNGVDP EEVVEQYGID
   661  TIRLYILFAA PPEKDILWDV KTDALPGVLR WQQRLWTLTT RFIEARASGK SPQPQLLSNK
   721  EKAEARKLWE YKNSVISQVT THFTEDFSLN SAISQLMGLS NALSQASQSV ILHSPEFEDA
   781  LCALMVMAAP LAPHVTSEIW AGLALVPRKL CAHYTWDASV LLQAWPAVDP EFLQQPEVVQ
   841  MAVLINNKAC GKIPVPQQVA RDQDKVHEFV LQSELGVRLL QGRSIKKSFL SPRTALINFL
   901  VQD

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LARS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.25
Highest tissue expression
12 nTPM

Expression across tissuesHPA

Tissue

  • basal ganglia: 12 nTPM
  • parathyroid gland: 12 nTPM
  • cerebral cortex: 11 nTPM
  • amygdala: 10 nTPM
  • midbrain: 9 nTPM
  • liver: 8.7 nTPM

Single-cell type

  • myonuclei: 127 nCPM
  • choroid plexus epithelial cells: 90 nCPM
  • ependymal cells: 87 nCPM
  • distal convoluted tubule cells: 78 nCPM
  • sertoli cells: 77 nCPM
  • cone photoreceptor cells: 77 nCPM

Immune cell

  • NK-cell: 2 nTPM
  • MAIT T-cell: 1.6 nTPM
  • gdT-cell: 1.3 nTPM
  • myeloid DC: 1.3 nTPM
  • memory B-cell: 1.1 nTPM
  • memory CD8 T-cell: 1.1 nTPM

Brain region

  • thalamus: 13 nTPM
  • hypothalamus: 11 nTPM
  • midbrain: 11 nTPM
  • basal ganglia: 10 nTPM
  • cerebellum: 10 nTPM
  • cerebral cortex: 10 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about LARS2.

Disease | AllUniProt

Conditions LARS2 is implicated in, by any mechanism.

  • Perrault syndrome 4 (PRLTS4) MIM:615300
  • Hydrops, lactic acidosis, and sideroblastic anemia (HLASA) MIM:617021

Disease | GeneticClinVar

65 pathogenic / likely-pathogenic of 633 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.86
gnomAD pLI
0
gnomAD missense Z
1.33
DepMap mean gene effect
-0.42
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of LARS2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LARS2 as an antibody target. Whether an autoantibody or antibody against LARS2 could matter depends on whether native LARS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LARS2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label LARS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/LARS2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...